Targeting and self-assembling peptides mimic fibrinogen coagulation for alleviating hypofibrinogenemia.

Area of Science:

• Biomaterials Science
• Hemostasis Research
• Nanotechnology

Background:

• Current treatments for fibrinogen deficiency and hypofibrinogenemia rely on blood-derived fibrinogen concentrate.
• This therapy faces limitations including supply shortages, viral risks, and high costs.

Purpose of the Study:

• To design a novel biomimetic peptide for hemostatic therapy.
• To overcome the limitations of current fibrinogen concentrate treatments.

Main Methods:

• A multifunctional peptide, SDGRG-C12-KLVFF-GRGDS (SC12FS), was designed to self-assemble.
• The peptide self-assembles into nanoparticles mimicking fibrinogen, targeting platelet receptors.
• Nanoparticles transform into nanofibers, forming fibrin-like networks for clot stabilization.

Main Results:

• The biomimetic peptide successfully mimicked fibrinogen's hemostatic function.
• SC12FS self-assembled into nanoparticles and then nanofibers, forming stable clots.
• The peptide demonstrated hemostatic efficacy and biosafety in rat and rabbit hypofibrinogenemia models.

Conclusions:

• The study presents a novel biomimetic peptide for safe and accessible hemostatic therapy.
• This approach offers an alternative to plasma-derived products for treating hypofibrinogenemia.
• The findings pave the way for overcoming limitations associated with current hemostatic treatments.